TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22357901
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of controlled-release oxycodone (CRO)
Study: 22357901
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of controlled-release oxycodone (CRO)
Study: 20075530
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (1 microg/kg)
Study: 12490344
Drug: Topiramate (300-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (300-400 mg/day)
Study: 28725257
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no relaxation therapy)
Study: 2144018
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion floxuridine (FUDR) at 0.15 mg/kg/d (IV) or 0.25 mg/kg/d (IA) for 14 days at monthly intervals.
Study: 7316249
Drug: Environmental Control
Normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental Control Unit (ECU) treatment, where patients were taken off all medication and not fed until leg pain and swelling disappeared (4 to 7 days).
Study: 7316249
Drug: Environmental Control
Normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental Control Unit (ECU) treatment with daily exercycle at 150 kpm for one mile to demonstrate absence of phlebitis.
Study: 7316249
Drug: Standard anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulant regime, bed rest, and support hose (control group).
Study: 7316249
Drug: Environmental Control
Normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental Control Unit (ECU) treatment.
Study: 31230466
Drug: Standard clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinical treatment (control group)
Study: 16368055
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg/day
Study: 9549743
Drug: Metoclopramide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.25 mg.kg-1)
Study: 7618677
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg droperidol added to 120 mg morphine in 60 ml saline
Study: 6734073
Drug: Glycerol 92
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol 92 mmol/l
Study: 6734073
Drug: Glycerol 272
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol 272 mmol/l
Study: 6734073
Drug: Glucose 76
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose 76 mmol/l
Study: 6734073
Drug: Glucose 215
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose 215 mmol/l
Study: 31404018
Drug: Imipenem 3
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem 3 × 500 mg intravenously daily
Study: 26972646
Drug: Cisplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (30 mg/m²) and Irinotecan (50 mg/m²) on day 1, 8, 22, 29 during 45 Gy radiation therapy (RT), 1.8 Gy per day over 5 weeks.
Study: 26972646
Drug: Cisplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (30 mg/m²) and Paclitaxel (50 mg/m²) on day 1, 8, 15, 22, 29 with RT, followed by adjuvant cisplatin (75 mg/m²) and paclitaxel (175 mg/m²) day 1 every 21 days for 3 cycles.
Study: 16322134
Drug: Modafinil (170-425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (170-425 mg once daily)
Study: 8390559
Drug: Prophylactic ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic ganciclovir (10 mg/kg/day)
Study: 8390559
Drug: Therapeutic ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic ganciclovir (10 mg/kg/day)
Study: 2442558
Drug: Lisinopril (1.25‐10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (1.25‐10.0 mg) administered on days 1 and 3
Study: 2442558
Drug: Lisinopril (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (oral and intravenous administration)
Study: 22503720
Drug: Xylazine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (0.05 mg/kg BW, i.m.)
Study: 20518174
Drug: Isotritinoin soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotritinoin soft capsule (taken orally)
Study: 20518174
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (control group 2)
Study: 12008199
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further loco-regional treatment (watch policy)
Study: 7819652
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (BCAAs) in a carbohydrate solution
Study: 2891798
Drug: Postoperative RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative RT plus chemotherapy with CAP (Cyclophosphamide, Adriamycin, and Cisplatin) for 6 months
Study: 2891798
Drug: Postoperative RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative RT plus chemotherapy with CAP
Study: 19464878
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with sufentanil 0.5 microg/mL
Study: 19464878
Drug: Levobupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine with sufentanil 0.5 microg/mL
Study: 16683215
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma levels of ACE (> 50 U/L)
Study: 16683215
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma levels of PAI-1 (> 43 ng/ml)
Study: 16683215
Drug: Thrombolytic agents
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agents with high ACE levels
Study: 9223815
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 micrograms/d for 6 weeks)
Study: 8387067
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy with 50 Gy in 25 daily fractions over 5 weeks
Study: 8387067
Drug: Cytotoxic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic therapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 31590692
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment of Vestibular Rehabilitation (VR) and Cognitive Behaviour Therapy (CBT) with eight sessions after a one-session Brief Intervention Vestibular Rehabilitation (BI-VR)
Study: 27621048
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide with oxygen (N2O/O2) via nasal mask, titrated to a maximum 70%:30% mixture during the procedure, with pre-procedure placebo pills.
Study: 27621048
Drug: Inhaled O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled O2 during the procedure and 5/325 mg hydrocodone/acetaminophen and 1 mg lorazepam pre-procedure (active control).
Study: 31626649
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (400 μg)
Study: 20090338
Drug: 100 U
Normalized name: vitamin E 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 U BT injection (Group A)
Study: 20090338
Drug: Balloon dilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon dilation plus 100 U BT injection (Group C)
Study: 17350629
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg daily of synthetic conjugated estrogens A
Study: 15188350
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg daily subcutaneous injection)
Study: 9669057
Drug: Mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 50 mg once daily
Study: 9669057
Drug: Mibefradil 150
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil 150 mg once daily
Study: 7833222
Drug: Perindoprilat (Pt,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat (Pt, 0.67 mg)
Study: 30106528
Drug: Two-step 0.454%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-step 0.454% SnF₂ dentifrice then 3% H₂O₂ whitening gel sequence
Study: 25486333
Drug: High-dose naringin
Normalized name: Naringin
DrugBank: Naringin (DB16859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naringin (1050 mg)
Study: 25486333
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 mg talinolol only)
Study: 21189384
Drug: HAI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI plus systemic therapy with bevacizumab (Bev)
Study: 21189384
Drug: HAI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI plus systemic therapy without bevacizumab (no Bev)
Study: 18285602
Drug: Breast intensity-modulated
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast intensity-modulated radiation therapy (IMRT)
Study: 16571277
Drug: SSLA 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSLA 200 mg in 250 ml of 5% glucose solution for intravenous dripping daily (test group A)
Study: 16571277
Drug: SSLA 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSLA 400 mg in 250 ml of 5% glucose solution for intravenous dripping daily (test group B)
Study: 16571277
Drug: DSI 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSI 20 ml daily (control group)
Study: 15072499
Drug: Newer approaches
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer approaches to the management of penile cancer including laser, photodynamic therapy, neoadjuvant therapy, and sentinel node mapping by lympho‐gamma‐scintigraphy.
Study: 10949722
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and non-steroidal anti-inflammatory drugs as needed
Study: 10700536
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (Group I)
Study: 30979026
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of data from both studies
Study: 27619174
Drug: Web-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based intervention with daily text-messaging (WB + M)
Study: 17388708
Drug: Atomoxetine (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (40-120 mg/day)
Study: 19421788
Drug: Acetaminophen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (750 mg PO every 6 hours)
Study: 15446778
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg once daily)
Study: 9696467
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of morphine (group A)
Study: 31833000
Drug: CAMBIA® 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMBIA® 50 mg
Study: 31833000
Drug: IM ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM ketorolac 60 mg
Study: 27918382
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion of meropenem (4 hours)
Study: 27918382
Drug: Conventional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional infusion of meropenem (30 minutes)
Study: 27918382
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion of meropenem
Study: 21488053
Drug: Caffeine (CAFF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAFF) 6 mg kg(‐1)
Study: 19581850
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg 90 minutes before surgery)
Study: 12098150
Drug: Liquid silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid silicone injections (6 injections of 0.2mL)
Study: 7594097
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (dosage group I: 0.3 mg/kg body weight bolus, 0.12 mg/kg per h for 24 h)
Study: 7594097
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (dosage group II: 0.5 mg/kg bolus, 0.24 mg/kg per h for 24 h)
Study: 7594097
Drug: Heparin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (150 IU/kg bolus, 20 IU/kg per h for 24 h)
Study: 7594097
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (dosage group I)
Study: 7594097
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (dosage group II)
Study: 2105792
Drug: Immunoscintigraphy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoscintigraphy with myosin antibody
Study: 2105792
Drug: Wall motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wall motion assessment at the site of antibody uptake
Study: 2164477
Drug: Propranolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (non-selective beta-blocker)
Study: 6108035
Drug: Metoprolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta 1-selective drug)
Study: 6108035
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Propranolol, Metoprolol)
Study: 28009680
Drug: Nonthermal focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonthermal focused ultrasound treatment (3 treatments at 2-week intervals)
Study: 28009680
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase (4-week before treatment)
Study: 28009680
Drug: Nonthermal focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonthermal focused ultrasound treatment
Study: 25671826
Drug: LAM add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM add-on combination therapy (100 mg LAM and 10 mg ADV per day)
Study: 25671826
Drug: ETV monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV monotherapy (0.5 mg ETV per day)
Study: 17722824
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for 30 days
Study: 17722824
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral Gliguidon or subcutaneous insulin)
Study: 15019802
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral DHEA daily for 4 weeks
Study: 11811112
Drug: Galstena treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galstena treatment
Study: 10215731
Drug: Ranitidine 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 125 mg
Study: 28815789
Drug: ED-initiated buprenorphine
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED-initiated buprenorphine treatment
Study: 28815789
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to community-based treatment
Study: 29402628
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia (TIVA) with propofol
Study: 18176118
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of erlotinib under fed conditions
Study: 18176118
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of erlotinib under fasting conditions
Study: 18176118
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of erlotinib daily for 8 days under feeding on day 8 after 7 days of fasting
Study: 18176118
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of erlotinib daily for 8 days under fasting on day 8 after 7 days of feeding
Study: 10203002
Drug: L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1 g intravenous dose)
Study: 2018901
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic solution injected at body temperature
Study: 2018901
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic solution injected at room temperature
Study: 31750800
Drug: Light-cured tetracaine-based
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Light-cured tetracaine-based anesthetic gel
Study: 30084882
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor monotherapy (PIM)
Study: 11090583
Drug: Head-down tilt
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-down tilt during Exercise treatment (15 min cycling at 70% maximal O2 uptake)
Study: 11090583
Drug: Head-up tilt
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-up tilt during Exercise treatment
Study: 11090583
Drug: Head-up tilt
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-up tilt during No-Exercise treatment (30 min resting)
Study: 11090583
Drug: Head-down tilt
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-down tilt during No-Exercise treatment
Study: 8476620
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg/kg (Group 1)
Study: 8476620
Drug: Ketamine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.5 mg/kg (Group 2)
Study: 8476620
Drug: Thiopental 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 3 mg/kg plus fentanyl 4 to 6 micrograms/kg (Group 3)
Study: 8476620
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg plus fentanyl 4 to 6 micrograms/kg (Group 4)
Study: 3510638
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g every four hours for four doses)
Study: 3510638
Drug: Moxalactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (2 g every four hours for four doses)
Study: 29792554
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg three times a day)
Study: 29792554
Drug: Methazolamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (100 mg twice a day)
Study: 22710649
Drug: Azilsartan medoxomil/chlorthalidone
Normalized name: Azilsartan Medoxomil/Chlorthalidone 40 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil/chlorthalidone 40/25 mg
Study: 22710649
Drug: Azilsartan medoxomil/chlorthalidone
Normalized name: Azilsartan Medoxomil/Chlorthalidone 40 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil/chlorthalidone 80/25 mg
Study: 22114906
Drug: Olmesartan/hydrochlorothiazide 40/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/hydrochlorothiazide 40/25 mg
Study: 10600919
Drug: Loxiglumide (CCK‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK‐A receptor antagonist) with intraduodenal fat and preload of banana shake
Study: 9428831
Drug: Acarbose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (3 x 100 mg/day)
Study: 29632615
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg PRN
Study: 27566855
Drug: Ranibizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 2.0 mg monthly (extra-large group, PEDs ≥352 μm)
Study: 25061716
Drug: Formula supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplemented with 8 g GOS/L (EF8)
Study: 25061716
Drug: Formula supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplemented with 4 g GOS/L (EF4)
Study: 22143621
Drug: Low-energy-dense (LE)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy-dense (LE) foods (30 kcal per 100 g)
Study: 22143621
Drug: High-energy-dense (HE)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy-dense (HE) foods (130 kcal per 100 g)
Study: 18410231
Drug: Moderately high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high salt intake (11.2 g/d) with high calcium diet (1284 mg)
Study: 18410231
Drug: Moderately low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately low calcium intake (518 mg)
Study: 18410231
Drug: Moderately high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high salt intake (11.2 g/d) with low calcium diet (518 mg)
Study: 18410231
Drug: Moderately low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately low salt intake (3.9 g/d) with low calcium diet (518 mg)
Study: 18410231
Drug: Moderately low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately low salt intake (3.9 g/d) with high calcium diet (1284 mg)
Study: 2066644
Drug: Control (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.9% saline solution)
Study: 11286044
Drug: Alprazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.75 mg daily)
Study: 1449200
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of four (40 ml) or eight (80 ml) ampules of antivenom
Study: 6731758
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia with enflurane-nitrous oxide (EFL)
Study: 21543992
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (prostaglandin analog)